Debiopharm initiates Phase IIb study of novel hepatitis C candidate
This article was originally published in Scrip
Executive Summary
Debiopharm has begun a Phase IIb study of its first-in-class non-immunosuppressive ciclosporin analogue, Debio 025, in combination with the standard-of-care regimen of pegylated interferon and ribavirin for the treatment of hepatitis C.